These dying patients cannot get experimental drugs


By AGENCY

Autumn Fuernisen was diagnosed four years ago with a terminal brain disorder, juvenile-onset Huntington's disease. Patients with rare diseases often have difficulty qualifying for compassionate use programs for experimental therapies.- Londen Tabor/TNS

AT 15, Autumn Fuernisen is dying.

She was diagnosed at age 11 with a rare degenerative brain disorder that has no known cure or way to slow it down: juvenile-onset Huntington’s disease.

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 31
Cxense type: NA
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights
   

Next In Health

Keeping our schools Covid-free when they reopen
This therapy can help prevent an autism diagnosis
Reducing the harm of tobacco for real
Surpassing six billion Covid-19 doses
Pfizer/BioNTech Covid-19 vaccine safe for primary schoolkids
‘Ebola is defeated’, says professor who discovered it
Bones need more than milk (and calcium)
‘Beautiful’ photos of the coronavirus reduces fear of infection
Suffering from runner’s knee? This is what's happening
This new drug proves effective for heart failure

Stories You'll Enjoy


Vouchers